MetaCap

Exagen Inc. (XGN)

NASDAQ: XGNHealth CareMedical SpecialitiesUSD

3.61-0.19 (-5.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$92.10M
EPS (TTM)
-$0.76
52-week range
2.59 – 9.22
Day range
3.48 – 3.90
Volume / Avg
508.83K / 470.43K
Beta
—

52-week range

$2.59$9.22

XGN stock today

On Nov 20, XGN ended the session at $3.61, shedding $0.19 (5.00%), versus the S&P 500's 3.70% decline. Shares are 60.8% below their 52-week high of $9.22, set on Oct 14, 2026 and 39.4% above the 52-week low of $2.59, near the bottom of the past year's range. XGN is down 40.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 52.6%.

Exagen has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Exagen

Company profile

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Industry
Medical Specialities
CEO
Mr. John Aballi
Headquarters
Vista, CA
Employees
216
IPO year
2019
Website
exagen.com

Financial highlights

Full financials

In fiscal 2025, Exagen generated $66.6 million in revenue, up 19.7% from fiscal 2024, its 3rd consecutive year of revenue growth. Exagen reported a net loss of $20.0 million, compared with a loss of $15.1 million a year earlier. Gross margin was 58.3% (down from 59.5%) and operating margin -21.1%.

Exagen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$66.58M$55.64M$52.55M$45.56M$48.30M
Growth+19.65%+5.89%+15.33%-5.66%+15.07%
Net income$-19.95M$-15.12M$-23.69M$-47.39M$-26.85M
EPS (diluted)$-0.93$-0.83$-1.34$-2.77$-1.68

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$10.29+185.04%

  • Strong buy 0
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.19 vs $-0.19

XGN news

All XGN news

Exagen peers

Health Care sector
XGN peer companies
CompanyPrice% ChgMarket capCompare
KEQUKewaunee Scientific Corporation33.55-2.75%$97.14Mvs XGN
BDSXBiodesix Inc.7.56-8.92%$83.83Mvs XGN
SERASera Prognostics Inc. Class A1.81-4.23%$71.98Mvs XGN
BNRBurning Rock Biotech Limited ADR13.24-0.60%$139.63Mvs XGN
TLSITriSalus Life Sciences Inc.2.32+6.67%$143.14Mvs XGN
MDXHMDxHealth SA0.1074-8.52%$10.25Mvs XGN
AMSAmerican Shared Hospital Services1.00-4.76%$6.67Mvs XGN
ACONAclarion Inc.1.22-13.92%$3.52Mvs XGN

Indexes, lists and sector

Exagen stock FAQ

What is Exagen's stock price today?

XGN last traded at $3.61 as of Nov 20, 4:00 PM EST, down 5.00% on the day. Prices are delayed at least 15 minutes.

Who is Exagen's CEO?

Mr. John Aballi is the chief executive officer of Exagen Inc., which has about 216 employees.

What is the XGN 52-week high?

The 52-week high for XGN is $9.22 and the 52-week low is $2.59. The stock is currently 60.8% below its high.

Compare XGN